Norovirus Evolution in Immunocompromised Patients
Author Information
Author(s): Izquierdo-Lara Ray W., Villabruna Nele, Hesselink Dennis A., Schapendonk Claudia M.E., Ribó Pons Sol, Nieuwenhuijse David, Meier Jenny I.J., Goodfellow Ian, Dalm Virgil A.S.H., Fraaij Pieter L.A., van Kampen Jeroen J.A., Koopmans Marion P.G., de Graaf Miranda
Primary Institution: Erasmus University Medical Center, Rotterdam, the Netherlands
Hypothesis
How does norovirus genetic diversity affect treatment efficacy in immunocompromised individuals?
Conclusion
Chronic norovirus infections in immunocompromised individuals lead to the evolution of antigenically distinct viral subpopulations, which can undermine treatment efficacy.
Supporting Evidence
- The P2 domain of the VP1 gene accumulated significantly more mutations than other regions.
- Some viral subpopulations were resistant to treatment with immunoglobulin preparations.
- Transmission of late-stage viruses was observed between two immunocompromised individuals.
Takeaway
Some sick people can have the same virus for a long time, and it can change a lot, making it harder to treat.
Methodology
Next-generation sequencing and clone-based sequencing of the VP1 gene were used to analyze norovirus diversity in stool samples from immunocompromised patients.
Potential Biases
Potential bias due to the limited sample size and the retrospective nature of some data collection.
Limitations
The small number of patients infected with non-GII.4 viruses limited the analysis of evolutionary patterns for other genotypes.
Participant Demographics
20 immunocompromised individuals with chronic norovirus infections.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website